🦊/Investors

Pura Vida Investments

Institutional investor

New York Β· Late Stage

Also known as PURA VIDA INVESTMENTS, LLC

Find your way into Pura Vida Investments

✨ Fox Verdict
Sign up to see your fit

Investment thesis

Pura Vida Investments is a fundamentally-driven manager investing across the healthcare sector, including medical technology, genomics and diagnostics, biopharmaceuticals, and health-tech. The firm seeks to identify company-specific valuation inflections and capitalize on structural changes and dislocations in healthcare. Its team of healthcare specialists with advanced medical, scientific, and financial degrees conducts exhaustive research and in-depth diligence on every position, forming differentiated views by focusing on under- or over-appreciated catalysts. The firm emphasizes long-term alignment with investors to generate alpha over the medium to long term, and applies analytical software tools and proprietary methods to evaluate large data sets.

Source: firm website, verified Sep 15, 2026.

Stage
Late Stage
HQ
New York, US
Instruments
Equity
Founded
2021
AUM
$91.5M
Tracked investments
7
IPOs
1
Acquisitions
1

What they invest in

from 7 of 7 portfolio companies

Medical Devices Γ—6Biotech Γ—4Healthtech Γ—4Deep Tech Γ—3AI & Machine Learning Γ—2Digital Health Γ—2Hardware Γ—2Mental Health Γ—1

HQs:United StatesΓ—6

Investments Β· 7 tracked

founders shown can be your intro path

By year:2022 Β· 32021 Β· 47 dated

Sonendosonendo.comOTC: SONXOct 2022 Β· $63M

Sonendo is a medical technology company that develops and manufactures the GentleWave System, a technology platform for treating tooth decay by cleaning and disinfecting the interior spaces of teeth without removing tooth structure.

HardwareHealthtechMedical DevicesLaguna Hills, US

Bjarne Bergheim(Executive Officer, Director)inJohn McGaugh(Executive Officer)inJohn Bostjancic(Executive Officer)Hugh Neuharth(Executive Officer)Roy T. Chen(Chief Talent Officer)Chris Guo(Interim Chief Financial Officer)in

Co-investorsEssex Woodlands Healthcare PartnersFjord VenturesGeneral AtlanticMeritech Capital PartnersOrbiMedWelsh, Carson, Anderson & Stowe

Cleerlycleerly.comin𝕏Jul 2022

Cleerly develops FDA-cleared, AI-driven analysis of noninvasive coronary CT (CCTA) imaging to characterize and quantify coronary artery disease.

AI & Machine LearningDigital HealthHealthtechMedical DevicesDenver, US

James Min, MD(Founder)inJames K. Min(Executive Officer, Director)in

BoardLee Cooper(Director)Peter Justin Klein(Director)Scott Barclay(Director)inLouis Samson(Director)

Co-investorsBattery VenturesBreyer CapitalDigiTx Partners LLCInsight PartnersLRVHealthEsplanade Ventures+4 more

Field Trip Healthfieldtriphealth.comin𝕏Mar 2021

Field Trip Health provides ketamine-assisted therapy for treatment-resistant depression and anxiety, offering rapid symptom relief through clinically monitored ketamine administration combined with psychotherapy.

Digital HealthHealthtechMedical DevicesMental Health

Co-investorsFrontera Technology VenturesEarl Grey CapitalJennison AssociatesSoleus CapitalSphera Funds Management

LUMICKSlumicks.comin𝕏Apr 2021 Β· $93M

LUMICKS develops life science research tools that measure and apply forces around biological interactions to link structural and 'omics analysis to functional outcomes at the molecular and cellular level.

BiotechDeep TechHardwareMedical Devices

Andrea(Co-founder & Chief Scientific Officer)Gerrit(Co-founder & Director of Product Management and Marketing)Hugo(CEO)Edmee(Chief Financial Officer)Hannah(HR Director)

Co-investorsLauxera Capital PartnersSoftBank Vision FundEuropean Investment BankGilde HealthcareIrving InvestorsT. Rowe Price

Metagenomimetagenomi.coin𝕏Jan 2022 Β· $175M

Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.

BiotechDeep TechMedical DevicesBerkeley, US

Brian Thomas(Executive Officer, Director, Promoter)in

BoardAndrew Farquharson(Director)inJak Knowles(Director)

Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesAgent CapitalFrazier Life SciencesHumboldt+5 more

Ultivueultivue.comin𝕏Apr 2021Acquired

Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US

George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in

Co-investorsARCH Venture PartnersNorthpond Ventures6 Dimensions CapitalAlly Bridge GroupApplied VenturesKilonova Capital+3 more

Other

Tracked investments with no reachable website or further public details β€” typically companies that wound down, renamed, or were absorbed.

NanoMosaic

Exits Β· 2

1 IPOs Β· 1 acquisitions Β· showing 1

SonendoOTC: SONX

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Pura Vida Investments made?
Pura Vida Investments has 7 tracked investments, 2 of which have exited.
What stage does Pura Vida Investments invest at?
Pura Vida Investments invests at the Late Stage stage.
What sectors does Pura Vida Investments focus on?
Pura Vida Investments focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Pura Vida Investments located?
Pura Vida Investments is headquartered in New York, US.

Similar investors

Featured in lists